Navigation Links
Stemedica Requests Pre-IND Meeting With FDA
Date:8/21/2009

SAN DIEGO, Aug. 21 /PRNewswire/ -- Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

Stroke is a leading cause of adult impairment, with 20% of stroke survivors requiring institutional care after 3 months and up to 30% severely and permanently disabled. The only approved treatments of acute ischemic stroke involves restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics (tPA) is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy.

"Following a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy," said Nikolai Tankovich, MD, PhD, President & Chief Medical Officer. "Treatment with allogeneic mesenchymal bone marrow cells may offer new hope to patients with chronic neurological or age-related, neurodegenerative diseases."

Allogeneic mesenchymal bone marrow cells are obtained from donors by extracting bone marrow and are expanded at Stemedica's cGMP compliant facility, which is licensed by the California Department of Public Health, Food and Drug Branch. "Stemedica's facility will manufacture clinical grade stem cells as it prepares for FDA approval of an IND to begin clinical trials," said Maynard Howe, PhD, Vice Chairman and CEO of Stemedica.

About Stemedica C
'/>"/>

SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
8. Biopure Reports on Meeting with the FDA
9. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  TeamHealth Medical Call Center (THMCC), a ... advice lines, announces its newly formed Clinical Advisory ... administrative leaders, provides clinical expertise to advance THMCC,s ... for hospital clients, physician clients and patients. ... it,s imperative to continuously advance our services and ...
(Date:5/23/2013)... 23, 2013 More than half of women ... from chemotherapy and still have excellent outcomes. To educate ... of the largest sources of online consumer information about ... Facebook page provide recently diagnosed women with information sources, ... chemotherapy. "We anticipate these innovative social media ...
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... 24, 2013 Residents of San Diego ... camp classes. Fitness expert, and Certified Russian Kettlebell Instructor, ... X Bootcamps in San Diego, California. The classes take ... class times offered. Initial sign-ups are available online ... been teaching Kettlebell for years. The bootcamps being ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
(Date:5/24/2013)... schizophrenics? Finding the answer for this is at the centre ... from the Bergen fMRI Group at the University of Bergen ... voices. The way they do this is by studying people ... a mental illness. For a five-year period, the group is ... recent report published in Frontiers in Human Neuroscience ...
(Date:5/24/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Type ... with signs of serious complications seen just a few ... on the latest results, it seems like type 2 ... Chiang, senior vice president of medical affairs and community ... faster, and it appears to be at a more ...
Breaking Medicine News(10 mins):Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Help at hand for schizophrenics 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 3
... New Executive LeadershipKOBE, Japan, March 5 Sysmex ... medical diagnostics instrument manufacturer and laboratory information systems ... Corporate and its subsidiaries in the Americas, Europe ... Obe will return to Sysmex Corporate after a ...
... more than 3,000 women in the U.S. and southern ... a vaginal microbicide gel for preventing HIV infection in ... Retroviruses and Opportunistic Infections (CROI), one 0.5 % dose ... to cells in the genital tract, was 30% effective. ...
... printing superstore was honored for ecommerce expertise when President Michael Del ... version of the highly respected Entrepreneur magazine. , ... ... Del Chiaro for the interview based on his proven success in ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... Inc. (RPI), a wholly owned subsidiary of Ranbaxy ... received approval from the U.S. Food and Drug ... Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg ... was submitted by Ranbaxy, from its Ohm Laboratories ...
... a penile extender every day for six months were able ... to 32% and their erectile function by up to 36%, ... issue of BJU International . , Researchers from San ... now suggesting that this treatment could provide a viable alternative ...
Cached Medicine News:Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2
... Our slimmest full-featured bronchofiberscope yet. The BF-3C40's ... by 0.2mm from the previous model. It ... Olympus models, thanks to the use of ... enlarge the image size by 70 percent. ...
... designed specifically to enable direct inspection of ... for pediatric applications as well. Its insertion ... 2.8mm across. As a result, insertion into ... greater ease. And since this sophisticated scope ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. , Lung Lavage. ...
... double lumen tube made of silicone rubber with ... to the characteristics of silicone rubber, Silbronco is ... insertion. Furthermore, the tube will not soften like ... term surgery., ,Silbronco is also especially useful ...
Medicine Products: